Insulet Corp. Files 2023 Annual Report on Form 10-K
Ticker: PODD · Form: 10-K · Filed: 2024-02-23T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, Annual Report, Insulet Corp, Medical Devices, Financials
TL;DR
<b>Insulet Corp. has submitted its annual 10-K filing for the fiscal year 2023, detailing its financial performance and business operations.</b>
AI Summary
INSULET CORP (PODD) filed a Annual Report (10-K) with the SEC on February 23, 2024. Insulet Corp. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is 100 Nagog Park, Acton, MA 01720. Insulet Corp. is incorporated in Delaware. The Standard Industrial Classification code for the company is 3841 (Surgical & Medical Instruments & Apparatus).
Why It Matters
For investors and stakeholders tracking INSULET CORP, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Insulet Corp.'s financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial information and risk factors disclosed in the 10-K are essential for investors and stakeholders to make informed decisions regarding their investments in Insulet Corp. (PODD).
Risk Assessment
Risk Level: medium — INSULET CORP shows moderate risk based on this filing. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing potential risks to its market position and financial performance.
Analyst Insight
Investors should review the detailed financial statements and risk factors in the 10-K to understand Insulet Corp.'s performance and potential challenges in the medical device market.
Key Numbers
- 2023-12-31 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
- 2024-02-23 — Filing Date (FILED AS OF DATE)
- 3841 — SIC Code (STANDARD INDUSTRIAL CLASSIFICATION)
Key Players & Entities
- INSULET CORP (company) — FILER
- 0001145197 (company) — ACCESSion NUMBER
- 20231231 (date) — CONFORMED PERIOD OF REPORT
- 20240223 (date) — FILED AS OF DATE
- 100 NAGOG PARK (address) — BUSINESS ADDRESS
- ACTON (city) — BUSINESS ADDRESS
- MA (state) — BUSINESS ADDRESS
- 01720 (zip) — BUSINESS ADDRESS
FAQ
When did INSULET CORP file this 10-K?
INSULET CORP filed this Annual Report (10-K) with the SEC on February 23, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by INSULET CORP (PODD).
Where can I read the original 10-K filing from INSULET CORP?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INSULET CORP.
What are the key takeaways from INSULET CORP's 10-K?
INSULET CORP filed this 10-K on February 23, 2024. Key takeaways: Insulet Corp. filed its 10-K report for the fiscal year ending December 31, 2023.. The filing covers the period from January 1, 2023, to December 31, 2023.. The company's principal business address is 100 Nagog Park, Acton, MA 01720..
Is INSULET CORP a risky investment based on this filing?
Based on this 10-K, INSULET CORP presents a moderate-risk profile. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing potential risks to its market position and financial performance.
What should investors do after reading INSULET CORP's 10-K?
Investors should review the detailed financial statements and risk factors in the 10-K to understand Insulet Corp.'s performance and potential challenges in the medical device market. The overall sentiment from this filing is neutral.
How does INSULET CORP compare to its industry peers?
Insulet Corp. operates in the medical device industry, specifically focusing on diabetes care technology. This sector is characterized by innovation, regulatory scrutiny, and a growing demand for advanced treatment solutions.
Are there regulatory concerns for INSULET CORP?
The medical device industry is subject to stringent regulations from bodies like the FDA. Companies must adhere to quality standards, manufacturing practices, and post-market surveillance requirements to ensure product safety and efficacy.
Industry Context
Insulet Corp. operates in the medical device industry, specifically focusing on diabetes care technology. This sector is characterized by innovation, regulatory scrutiny, and a growing demand for advanced treatment solutions.
Regulatory Implications
The medical device industry is subject to stringent regulations from bodies like the FDA. Companies must adhere to quality standards, manufacturing practices, and post-market surveillance requirements to ensure product safety and efficacy.
What Investors Should Do
- Review Insulet Corp.'s detailed financial statements for the fiscal year 2023.
- Analyze the risk factors section to understand potential challenges and uncertainties.
- Compare key financial metrics with previous years to identify trends and performance changes.
Key Dates
- 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
- 2024-02-23: Filing Date — Date the 10-K report was officially submitted to the SEC.
Year-Over-Year Comparison
This filing represents the annual 10-K for the fiscal year 2023, providing a comprehensive update compared to previous filings which would include quarterly reports (10-Q) and potentially other material event disclosures.
From the Filing
0001145197-24-000011.txt : 20240223 0001145197-24-000011.hdr.sgml : 20240223 20240222174933 ACCESSION NUMBER: 0001145197-24-000011 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 162 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240223 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 24666426 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 10-K 1 podd-20231231.htm 10-K podd-20231231 false 2023 FY 0001145197 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member P3Y http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#LongTermDebtCurrent http://fasb.org/us-gaap/2023#LongTermDebtCurrent http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations 0.0044105 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent 365 0001145197 2023-01-01 2023-12-31 0001145197 2023-06-30 iso4217:USD 0001145197 2024-02-15 xbrli:shares 0001145197 2023-12-31 0001145197 2022-12-31 0001145197 us-gaap:NonrelatedPartyMember 2023-12-31 0001145197 us-gaap:NonrelatedPartyMember 2022-12-31 0001145197 us-gaap:RelatedPartyMember 2023-12-31 0001145197 us-gaap:RelatedPartyMember 2022-12-31 iso4217:USD xbrli:shares 0001145197 us-gaap:NonrelatedPartyMember 2023-01-01 2023-12-31 0001145197 us-gaap:NonrelatedPartyMember 2022-01-01 2022-12-31 0001145197 us-gaap:NonrelatedPartyMember 2021-01-01 2021-12-31 0001145197 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001145197 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001145197 us-gaap:RelatedPartyMember 2021-01-01 2021-12-31 0001145197 2022-01-01 2022-12-31 0001145197 2021-01-01 2021-12-31 0001145197 us-gaap:CommonStockMember 2020-12-31 0001145197 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001145197 us-gaap:RetainedEarningsMember 2020-12-31 0001145197 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001145197 2020-12-31 0001145197 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001145197 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001145197 podd:ConvertibleSeniorNotes1.375Member 2021-12-31 xbrli:pure 0001145197 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001145197 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001145197 us-gaap:CommonStockMember 2021-12-31 0001145197 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001145197 us-gaap:RetainedEarningsMember 2021-12-31 0001145197 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001145197 2021-12-31 0001145197 us-gaap:AdditionalPaidInCapitalMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001145197 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001145197 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001145197 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001145197 us-gaap:AdditionalPaidInCapitalMember